BioXcel Therapeutics (BTAI) Announces $200M Proposed Public Offering of Common Stoc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
July 27, 2020 4:21 PM EDTNEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase up to $30.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions.
BofA Securities, Goldman Sachs & Co. LLC, Jefferies, Guggenheim Securities and SunTrust Robinson Humphrey are acting as book-running managers for the... More
